missing translation for 'onlineSavingsMsg'
Learn More
Learn More
PDGFRA Monoclonal Antibody (OTI4G5), TrueMAB™, OriGene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA807658S
This item is not returnable.
View return policy
Description
PDGFRA Monoclonal antibody specifically detects PDGFRA in Human samples. It is validated for Western BlotSpecifications
| PDGFRA | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| P16234 | |
| Mouse | |
| Affinity chromatography | |
| RUO | |
| 5156 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| IgG2b |
| Western Blot | |
| OTI4G5 | |
| Unconjugated | |
| PDGFRA | |
| AI115593; alpha platelet-derived growth factor receptor; Alpha platelet-derived growth factor receptor precursor (PDGF-R-alpha); alpha-type platelet-derived growth factor receptor; APDGFR; CD140 antigen-like family member A; CD140A; CD140a antigen; GAS9; MGC74795; OTTHUMP00000218656; PDGF A-chain; PDGF alpha chain; PDGF Receptor alpha; PDGF subunit A; PDGF-1; PDGFACE; PDGFR2; Pdgfr-2; PDGFRA; pdgfr-a; PDGFRA/BCR fusion; PDGF-R-alpha; PDGFR-alpha; platelet derived growth factor receptor alpha; platelet derived growth factor receptor, alpha polypeptide; platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; platelet-derived growth factor receptor alpha; platelet-derived growth factor receptor, alpha polypeptide; rearranged-in-hypereosinophilia-platelet derived growth factor receptor alpha fusion protein; RHEPDGFRA | |
| Human recombinant protein fragment corresponding to amino acids 789-1089 of human PDGFRA produced in E.coli. | |
| 30 μL | |
| Primary | |
| Human | |
| Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction